Literature DB >> 33453401

A Prospective, Blinded Assessment of Ammonia Testing Demonstrates Low Utility Among Front-Line Clinicians.

Juan J Gonzalez1, Elliot B Tapper2.   

Abstract

Although ammonia is essential to the pathophysiology of hepatic encephalopathy (HE), its levels cannot diagnose HE, do not correlate with the grade of HE, and are plagued by technical challenges.1 Nevertheless, ammonia levels are routinely obtained in the evaluation of hospitalized patients.2 We have advocated for quality improvement to limit testing.3 However, data are lacking regarding the reasons for, context, and perceived value of ammonia testing among ordering clinicians. Additional data are needed to optimize a quality improvement intervention aiming to curb overuse.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33453401      PMCID: PMC8275656          DOI: 10.1016/j.cgh.2021.01.016

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  A Decision Support Tool to Reduce Overtesting for Ceruloplasmin and Improve Adherence With Clinical Guidelines.

Authors:  Elliot B Tapper; Neil Sengupta; Michelle Lai; Gary Horowitz
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

2.  Adherence to Recommended Inpatient Hepatic Encephalopathy Workup.

Authors:  Dennis Kumral; Rehan Qayyum; Susan Roseff; Richard K Sterling; Mohammad S Siddiqui
Journal:  J Hosp Med       Date:  2019-03       Impact factor: 2.960

3.  Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.

Authors:  Jasmohan S Bajaj; Mette Lauridsen; Elliot B Tapper; Andres Duarte-Rojo; Robert S Rahimi; Puneeta Tandon; Debbie L Shawcross; Dominique Thabut; Radha K Dhiman; Manuel Romero-Gomez; Barjesh C Sharma; Sara Montagnese
Journal:  Am J Gastroenterol       Date:  2020-07       Impact factor: 10.864

4.  Low-Value Levels: Ammonia Testing Does Not Improve the Outcomes of Overt Hepatic Encephalopathy.

Authors:  Elliot B Tapper; Robert S Rahimi
Journal:  Am J Gastroenterol       Date:  2020-05       Impact factor: 10.864

5.  Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.

Authors:  Mona Haj; Don C Rockey
Journal:  Am J Gastroenterol       Date:  2020-05       Impact factor: 10.864

6.  A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy.

Authors:  Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-11-03       Impact factor: 11.382

7.  Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.

Authors:  Robert S Rahimi; Rifaat Safadi; Dominique Thabut; Kalyan Ram Bhamidimarri; Nikolaos Pyrsopoulos; Amy Potthoff; Stan Bukofzer; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

  7 in total
  4 in total

Review 1.  Missed diagnosis of cirrhosis in the inpatient setting.

Authors:  Alpesh N Amin; Peter H Nguyen; Elliot B Tapper
Journal:  J Hosp Med       Date:  2022-08       Impact factor: 2.899

2.  Serum ammonia use: unnecessary, frequent and costly.

Authors:  Elizabeth Aby; Andrew P J Olson; Nicholas Lim
Journal:  Frontline Gastroenterol       Date:  2021-08-18

Review 3.  Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

Authors:  Sasha Deutsch-Link; Andrew M Moon; Yue Jiang; A Sidney Barritt; Elliot B Tapper
Journal:  Clin Ther       Date:  2022-02-04       Impact factor: 3.637

Review 4.  Insight into microRNAs-Mediated Communication between Liver and Brain: A Possible Approach for Understanding Acute Liver Failure?

Authors:  Karolina Orzeł-Gajowik; Krzysztof Milewski; Magdalena Zielińska
Journal:  Int J Mol Sci       Date:  2021-12-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.